Literature DB >> 22420312

Nuclear-targeted drug delivery of TAT peptide-conjugated monodisperse mesoporous silica nanoparticles.

Limin Pan1, Qianjun He, Jianan Liu, Yu Chen, Ming Ma, Linlin Zhang, Jianlin Shi.   

Abstract

Most present nanodrug delivery systems have been developed to target cancer cells but rarely nuclei. However, nuclear-targeted drug delivery is expected to kill cancer cells more directly and efficiently. In this work, TAT peptide has been employed to conjugate onto mesoporous silica nanoparticles (MSNs-TAT) with high payload for nuclear-targeted drug delivery for the first time. Monodispersed MSNs-TAT of varied particle sizes have been synthesized to investigate the effects of particle size and TAT conjugation on the nuclear membrane penetrability of MSNs. MSNs-TAT with a diameter of 50 nm or smaller can efficiently target the nucleus and deliver the active anticancer drug doxorubicin (DOX) into the targeted nucleus, killing these cancer cells with much enhanced efficiencies. This study may provide an effective strategy for the design and development of cell-nuclear-targeted drug delivery.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22420312     DOI: 10.1021/ja211035w

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  127 in total

1.  Cell-penetrating peptide enhanced intracellular Raman imaging and photodynamic therapy.

Authors:  Andrew M Fales; Hsiangkuo Yuan; Tuan Vo-Dinh
Journal:  Mol Pharm       Date:  2013-05-09       Impact factor: 4.939

2.  Fluorometric nanoprobes for simultaneous aptamer-based detection of carcinoembryonic antigen and prostate specific antigen.

Authors:  Yali Sun; Jianfeng Fan; Linyan Cui; Wei Ke; Fangjie Zheng; Yuan Zhao
Journal:  Mikrochim Acta       Date:  2019-02-02       Impact factor: 5.833

3.  TAT peptide-functionalized gold nanostars: enhanced intracellular delivery and efficient NIR photothermal therapy using ultralow irradiance.

Authors:  Hsiangkuo Yuan; Andrew M Fales; Tuan Vo-Dinh
Journal:  J Am Chem Soc       Date:  2012-07-09       Impact factor: 15.419

4.  Interaction of SQSTM1 with the motor protein dynein--SQSTM1 is required for normal dynein function and trafficking.

Authors:  Luis Calderilla-Barbosa; M Lamar Seibenhener; Yifeng Du; Maria-Theresa Diaz-Meco; Jorge Moscat; Jin Yan; Marie W Wooten; Michael C Wooten
Journal:  J Cell Sci       Date:  2014-07-11       Impact factor: 5.285

Review 5.  The practicality of mesoporous silica nanoparticles as drug delivery devices and progress toward this goal.

Authors:  Robert Roggers; Shrey Kanvinde; Suthida Boonsith; David Oupický
Journal:  AAPS PharmSciTech       Date:  2014-05-29       Impact factor: 3.246

Review 6.  Subchronic and chronic toxicity evaluation of inorganic nanoparticles for delivery applications.

Authors:  Raziye Mohammadpour; Marina A Dobrovolskaia; Darwin L Cheney; Khaled F Greish; Hamidreza Ghandehari
Journal:  Adv Drug Deliv Rev       Date:  2019-07-08       Impact factor: 15.470

7.  Peptide conjugated magnetic nanoparticles for magnetically mediated energy delivery to lung cancer cells.

Authors:  Anastasia K Hauser; Kimberly W Anderson; J Zach Hilt
Journal:  Nanomedicine (Lond)       Date:  2016-07-07       Impact factor: 5.307

8.  TAT-OSBP-1-MKK6(E), a novel TAT-fusion protein with high selectivity for human ovarian cancer, exhibits anti-tumor activity.

Authors:  Jiali Zhong; Jiali Kang; Xiaoxia Wang; Wenyan Jiang; Hua Liao; Jin Yuan
Journal:  Med Oncol       Date:  2015-03-18       Impact factor: 3.064

9.  Targeted iron oxide nanoparticles for the enhancement of radiation therapy.

Authors:  Anastasia K Hauser; Mihail I Mitov; Emily F Daley; Ronald C McGarry; Kimberly W Anderson; J Zach Hilt
Journal:  Biomaterials       Date:  2016-07-26       Impact factor: 12.479

10.  Shining light on nuclear-targeted therapy using gold nanostar constructs.

Authors:  Duncan Hieu M Dam; Kayla S B Culver; Patrick N Sisco; Teri W Odom
Journal:  Ther Deliv       Date:  2012-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.